{"id":"3ed41ee539c4","type":"article","url":"https://hartvaat.nl/2016/11/22/management-van-klinisch-significante-geneesmiddelinteracties-met-statines-aha-aa/","title":"Management van klinisch significante geneesmiddelinteracties met statines: AHA-aanbevelingen","title_en":"Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts"],"tags":["gepersonaliseerde-geneeskunde","laminopathie","statines","vrouwen"],"journal":"Circulation","doi":"10.1161/CIR.0000000000000456","source_url":"https://doi.org/10.1161/CIR.0000000000000456","authors":["Barbara S Wiggins","Joseph J Saseen","Robert L Page","Brent N Reed","Kevin Sneed","John B Kostis","David Lanfear","Salim Virani","Pamela B Morris"],"significance":8,"published":"2016-11-22","source_date":"2016-11-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ezetimib/"],"congress":"","summary_en":"This AHA scientific statement provided recommendations for managing clinically significant drug interactions with statins, covering interactions with commonly used cardiovascular medications and strategies to minimize the risk of myopathy and rhabdomyolysis.","created":"2026-07-03T10:26:25Z","updated":"2026-07-03T13:25:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"AHA scientific statement met aanbevelingen voor het management van klinisch significante geneesmiddelinteracties met statines bij cardiovasculaire patiënten. Praktijkgids voor veilig combinatiegebruik.","abstract_original":""}